Overall, if you are looking for a gentle and pH-balanced solution for your soft contact lenses, then the Sensitive Eyes Contact Lens Solution by Bausch & Lomb is definitely worth considering.

Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better ...

The collaboration may expand into other ocular conditions. Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments for age ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire ...

VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the ...

Evercore ISI lowered the firm’s price target on Bausch + Lomb (BLCO) to $22 from $25 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science ...

George Medicines has entered into an exclusive licensing and supply agreement with Bausch Health (BHC) Companies granting Bausch Health ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...